Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
出版年份 2010 全文链接
标题
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
作者
关键词
-
出版物
BLOOD
Volume 116, Issue 6, Pages 926-934
出版商
American Society of Hematology
发表日期
2010-05-04
DOI
10.1182/blood-2009-10-248609
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Understanding and circumventing resistance to anticancer monoclonal antibodies
- (2010) Lina Reslan et al. mAbs
- Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN- 2a Therapy in Metastatic Renal Cell Carcinoma Patients
- (2009) T. Schwaab et al. CLINICAL CANCER RESEARCH
- Ten years of rituximab in NHL
- (2009) Matthew C Winter et al. Expert Opinion On Drug Safety
- Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders
- (2009) Jorge Castillo et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Mechanisms of Foxp3+ T Regulatory Cell-Mediated Suppression
- (2009) Ethan M. Shevach IMMUNITY
- Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
- (2009) Franck Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic Effect of Dendritic Cell Vaccination and Anti-CD20 Antibody Treatment in the Therapy of Murine Lymphoma
- (2009) Zohar Gadri et al. JOURNAL OF IMMUNOTHERAPY
- Monoclonal antibodies for cancer immunotherapy
- (2009) Louis M Weiner et al. LANCET
- Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention
- (2009) Claudia Stolz et al. LEUKEMIA & LYMPHOMA
- A Decade of Rituximab: Improving Survival Outcomes in Non-Hodgkin's Lymphoma
- (2008) Arturo Molina Annual Review of Medicine
- Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV
- (2008) V. Minard-Colin et al. BLOOD
- Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
- (2008) Christophe de Romeuf et al. BRITISH JOURNAL OF HAEMATOLOGY
- Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
- (2008) R. J. Amato et al. CLINICAL CANCER RESEARCH
- Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines
- (2008) F. O. Smith et al. CLINICAL CANCER RESEARCH
- Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
- (2008) Ronald P Taylor et al. CURRENT OPINION IN IMMUNOLOGY
- The immunogenicity of tumor cell death
- (2008) Oliver Kepp et al. CURRENT OPINION IN ONCOLOGY
- Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs
- (2008) Peter S. Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies
- (2008) Julien Lejeune et al. JOURNAL OF CLINICAL ONCOLOGY
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study
- (2008) Guillaume Cartron et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search